Interventional Glaucoma

L. Jay Katz, MD, provides some key takeaways from his Glaucoma 360 2023 presentation, "Steroid Induced Glaucoma Management."

Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.

Ying Han, MD, PhD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Tube shunt update."

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.

Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.

According to the company, the approval allows Eyenuk’s EyeArt AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss.

Minimally invasive, novel system achieves significant pressure level reductions.

Unless there is an underlying medical necessity, researchers discourage the application of atropine as a standard therapy for trabeculectomy surgery in a recent study.

Tailored approach can help physicians provide better outcomes for patients

Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, speak with Ophthalmology Times® on what attendees can expect from the upcoming meeting, being held Feb. 2-4 in downtown San Francisco.

Based on their findings, an international team of researchers is discouraging the application of atropine as a standard therapy for trabeculectomy surgery.

All events in the 2023 annual gathering, scheduled for February 2 to 4 in downtown San Francisco, California, will take place at a new venue, The Westin St Francis San Francisco on Union Square.

Patient-tailored techniques result in predicable outcomes for patients.

Until new innovations began transforming the field a decade ago, ophthalmologists had a limited toolbox. This option allows ophthalmologists to provide positive outcomes for their patients.

BVS Sight Inc. was created through a partnership between Boomerang Ventures and Purdue Research Foundation.

The technology uses excimer laser energy to create microscopic openings in the trabecular meshwork to re-establish the natural flow of aqueous.

New educational campaign aims to educate individuals at risk for glaucoma and raise funding for glaucoma research.

Janey Wiggs, MD, PhD, associate chief of Ophthalmology Clinical Research at Massachusetts Eye & Ear discusses genetics of glaucoma, providing an overview of what is known about genes and gene mutations that can cause or contribute to glaucoma.

Investigators' data showed that overweight/obesity, migraine, asthma, and smoking are major risk factors for conversion from ocular hypertension to open-angle glaucoma in this Spanish and Portuguese population.

According to a team of investigators from the University of Michigan, the findings could help inform treatments for blindness in humans.

The technology is used to treat glaucoma at the same time as cataract surgery.

The company anticipates introducing latanoprost ophthalmic solution 0.005% to U.S. eye care practitioners in the second half of 2023.

The drug is expected to be available to eye care clinicians in the US during the second half of 2023.

Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

A new device for goniotomy has the advantage of an irrigation/aspiration system, which offers easier excision of the trabecular meshwork and better visibility. Dr Desai shares his experiences using the device as well as his tips and surgical pearls for success.